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Background: The term “reproductive, maternal, newborn, and child health (RMNCH)” describes an integrated
continuum of health states which is central to Millennium Development Goals 4 and 5. While the burden of
mortality and morbidity associated with RMNCH is well known, knowledge is still limited about the economic
burden of RMNCH. Concrete evidence of cost of illness (COI) of RMNCH may help policy makers in supporting
investment in RMNCH.
Methods: A systematic literature search of COI studies was performed in electronic databases. The time
frame for the analysis was January 1990 – April 2011. The databases checked were Medline (Pubmed), Embase
and ECONbase, EconLit, the Cumulative Index to Nursing and Allied Health (CINAHL), the National Bureau of
Economic Research, the Latin American and Caribbean Literature on Health Sciences Database (LILACS),
and Popline. Furthermore, we searched working papers and reference lists of selected articles.
Results: All the studies investigated address particular complications and issues of RMNCH, e.g., preterm birth,
non-exclusive breastfeeding, and sexually transmitted diseases (STDs), but not RMNCH as an entire continuum.
Most of the studies were conducted in high income countries, with limited data on low and middle income
countries. The burden of disease is very high even for single complications. For example, the disease burden
related to non-exclusive breastfeeding was given as 14.39 billion international dollars (ID) (2012, purchasing
power parity) per year in the USA. Methodological differences in study design, costing approach, perspective
of analysis, and time frame make it difficult to compare different studies.
Conclusion: The continuum of RMNCH covers a large portion of the lifespan from birth through the reproductive age.
From a methodological perspective, an ideal COI study would clearly describe the perspective of analysis and, hence,
the cost items (direct or indirect), cost collection procedure, discounting, quality of data, time frame of analysis, related
comorbidities, and robust sensitivity analysis for all the assumptions. Further research is needed to measure the
economic impact of RMNCH, including identification of the most cost-effective policy and interventions for
prevention, reduction, and elimination of the complications of RMNCH.
Keywords: Cost of illness; Reproductive health; Maternal health; Breastfeeding; Preterm birth* Correspondence: sanjib.saha@med.lu.se
1Center for Primary Healthcare Research, Skåne University Hospital, Lund
University/Region Skåne, Jan Waldenströms gata 35, Malmö SE-205 02, Sweden
2Health Economics & Management, Institute of Economic Research, Lund
University, Tycho Brahes väg 1, SE- 220 07, Lund, Sweden
Full list of author information is available at the end of the article
© Saha and Gerdtham; licensee Springer. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
2013
Saha and Gerdtham Health Economics Review Page 2 of 122013, 3:24
http://www.healtheconomicsreview.com/content/3/1/24Review
Background
“Reproductive, maternal, newborn, and child health
(RMNCH)” refers to an effective and integrated con-
tinuum of care that delivers essential services and
interventions to women facing particular risk arising
from reproduction and pregnancy, their infants at critical
points, and children in their first 5 years of age [1]. An
RMNCH program is fundamental to development, as
reflected in Millennium Development Goals (MDGs) 4
(reducing under-5 child mortality by two-thirds between
1990 and 2015) and 5 (reducing maternal mortality by
three-quarters between 1990 and 2015 (5A), and achieving
universal access to reproductive health by 2015 (5B) [2].
The current global under-5 mortality rate needs to be
halved from 57 deaths per 1,000 live births to 29 to
reach the target by 2015 [3]. Even when a country is on
track with the goals, deep inequalities still persist, with
the poorest communities continuing to experience far less
progress than the richest [4]. Despite increased attention
to maternal mortality and presence of interventions to
address maternal health, current health systems and
financial commitments for RMNCH may not be sufficient
to achieve MDG 5A [5]. Research has shown that 80%
of deaths in the maternal group could be averted if
women had access to essential maternity and basic
health care [5,6]. Reproductive health, including family
planning, saves infant and maternal lives and reduces
unintended births [7]. The progress towards MDG 5B is
slow and uneven. In 2009, the contraceptive prevalence
rate was 63% globally [8], but one in four Sub-Saharan
African women still had an unmet need for family planning.
Globally, during 1990–2009, 65% of births were attended
by a skilled health worker, compared to 48% in Africa [9].
There has been insufficient investment to ensure that
maternal and reproductive health services are accessible,
affordable, and available on an equitable basis [10].
Cost of illness (COI) studies identify different compo-
nents of costs of particular diseases or disease-related
complications in different sectors of the society, which
might have been saved if the diseases did not exist. This
information can help policy makers to grasp the economic
burden of the diseases or complications, and justify
interventions [11]. Research of the economic burden
of RMNCH diseases seems inadequate [12] and a concise
review of available knowledge and evidence is required.
Therefore, the aim of this report was to systematically
review the literature on COI or disease burden for
RMNCH and related complications.
Methodology
Methodological issues in cost of illness studies
Cost is the value of a resource, conceptually defined as
the value that could be gained by using the resource in analternative way. Economists use the concept “opportunity
cost” or “economic cost” when conducting COI studies.
Opportunity cost is the cost of an alternative that must be
forgone in order to pursue an action or intervention. It
is assumed that scarce resources always have a cost
even if no money is spent because the resources could
be efficiently used elsewhere.
The key idea behind economic cost estimation is that
when resources are used to provide health care for one
person, they are simply not available for other people
or alternative societal uses. The methodological aspects
of COI can be organized into the following broad
categories:
Types of costs
The economic costs of a disease can be classified as direct,
indirect, and intangible costs. Direct costs are all direct
medical cost and direct non-medical costs. Direct medical
costs are expenditures for diagnosis, treatment, continuing
care, rehabilitation, and terminal care for an illness.
Direct non-medical costs are the costs of non-health
care resources, such as transportation to and from health
care providers, certain household expenditures, costs of
relocating and certain property losses, legal and court
costs, and informal care [13]. Informal care is the care
provided by family members or friends to the sick person.
Indirect cost is the productivity loss cost due to
morbidity and mortality. There is a misperception of
the term “indirect costs” in COI studies because it is
used for costing of overhead and other shared costs at the
patient level within the health care services accounting
framework. Some researchers have suggested substituting
the term “indirect costs” with “productivity costs” [14].
However, in this article, we use “indirect cost” in line
with the previous World Health Organization (WHO)
report [15].
The intangible costs capture the psychological dimen-
sions of illness, including pain, bereavement, anxiety, and
suffering. These types of costs are hard to measure and
are usually not included in COI studies [11].
Perspectives
Cost of illness studies may be conducted from different
perspectives which determine the types of cost included
in the analysis. These perspectives may measure costs to
society, the health care systems, participants and their
families, and third party payers (Table 1).
The perspective of COI studies needs to be clearly stated
because each study included covers slightly different
costs. The purpose of a study ultimately determines the
perspective. A study that takes the health care systems
perspective needs to include only medical care-related
costs. The societal perspective is more comprehensive
and is consequently often recommended by researchers
Table 1 Costs included in cost of illness (COI) studies using different perspectivesa
Perspective Medical cost Cost of lost productivity
(due to morbidity and mortality)
Non-medical cost (time cost,
informal care, transportation)
Transfer payment
Societal All All All Administration cost and excess
burden of taxes
Health care system All – – –
Participants and
their families
Out of pocket costs Lost wages or
household production
Out of pocket costs Amount received
Third party payer Covered cost Covered cost – Amount paid by others +
administration cost
Adapted from Gold et al. [14] and Segel JE [16]. aThis is a general categorization and may not apply to all cases.
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indirect) except transfer payments (a shift of resources
such as social security benefits or Medicare, Medicaid
payments) [16].
Costing approach
Cost of illness studies may be based on different combina-
tions of costing approaches, as discussed below, in their
application:
 Incidence or prevalence-based approaches
 Top-down or bottom-up approaches
 Prospective or retrospective approaches
Incidence and prevalence-based studies Incidence-based
studies estimate the lifetime costs of a disease from its
onset to its termination, which include the discounted
morbidity and mortality costs for the incident cohort,
usually calculated based on the year when the disease
first appeared. Morbidity costs are defined as the value
of income lost from decreased productivity, restricted
activity, absenteeism, and bed days. Mortality costs are
the value of future income lost by premature death.
Prevalence-based studies estimate the costs of all
disease cases (new as well as pre-existing) in a given
year. They include all medical care costs and morbidity
costs for a disease within the study year.
Each approach has benefits and drawbacks. However,
prevalence-based studies are rather common because
they require less data and fewer assumptions compared
to incidence-based studies, and are less expensive to
conduct. The prevalence-based approach is suitable
for measuring the total current economic burden of a
disease. Prevalence-based studies provide a snap shot
of the disease and may not capture the progression of
the disease at various stages. Therefore, they may capture
the end stage of a disease which may not be avoidable.
For this reason, prevalence-based studies are not per-
fectly suitable for measuring the potential savings from
preventive interventions. They are, however, suitable
for diseases where costs remain relatively stable over
a time period. Incidence-based studies provide an estimateof the savings potentially accrued if the preventive
measure is implemented. These are also helpful in
analyzing the management of illness from the onset of
disease till recovery or death. This provides a better
picture of how the cost increases or decreases as the
diseases progresses and consequently allows policy makers
to plan interventions targeting specific stages of disease
and/or specific population groups [11,13,16].A top-down (population-based) or bottom-up (person-
based) approach Two approaches that are commonly
used for quantifying the resources are the top-down
(population-based) and the bottom-up (person-based)
approach. The top-down approach estimates economic
costs by using aggregate data on mortality, morbidity,
hospital admissions, general practice consultations,
disease-related costs, and other health-related indicators.
Various sources and types of data are used to calculate
the fractions of resources used that can be attributed to
each disease. Generally this information is collected from
national health care statistics, patient registers, insurance
databases, etc. One disadvantage of the top-down
approach is that not all costs are usually included in
the database (e.g., costs for informal care and the patient’s
time cost are not included). For complex diseases, the
top-down approach may underestimate or overestimate
the costs caused by comorbidities related to the disease
of interest and there is a risk of misclassification if a
diagnosis-based classification is used. The top-down
approach is limited to providing cost estimates stratified
by disease subtypes, severity, and patient characteristics
and demographic variability. The bottom-up approach
calculates the resources used and productivity loss in
individuals with the health problem in question. The
mean per-person costs are then extrapolated to the
whole population with relevant epidemiological data. In
this case, the patient sample size needs to be unbiased
and representative of the national population. The bottom-
up approach is more comprehensive and enables detection
of the variability related to differences in important
demographic characteristics between patients [11,13,16].
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retrospective COI studies, all events have already occurred
by the time the study is initiated. The researchers go back
to collect the resources used and adjust these to the base
year price. By contrast, in prospective COI studies, the
relevant events have not yet occurred when the study is
initiated and the researchers follow patients over time to
collect the data. Both prevalence and incidence studies
can be either prospective or retrospective. Retrospective
studies are less expensive and less time-consuming;
however, they can only be carried out when sufficient
data is available. In prospective analysis, researchers can
design the data collection methods and get details of cost
items (e.g., patient transportation cost, time cost), which
may not be possible in retrospective analysis without
any additional assumptions. Prospective analysis is not
suitable if the duration of disease is long, which might
affect the participant and therefore hamper the quality
of the data [11].
Discounting
Discounting is a method used to capture an individual’s
preference for income today rather than his or her
income in the future. Discounting allows calculation of
the present value of payments that will occur in the future.
The appropriate discount rate varies in the scientific
literature but the WHO uses a 3% discount rate [17].
Indirect cost calculation method
Although there is not universal agreement about including
indirect cost in COI, or about how to estimate indirect
costs, indirect cost calculation is common practice. There
are two commonly used methods: the human capital
approach (HCA) and the friction cost approach (FCA).
The HCA estimates total production losses due to illness,
premature death, or disability by calculating the total
period of absence and multiplying this by the average
wage rate of the absent worker. Calculations using HCA
often include the value of household work, usually valued
as the opportunity cost of hiring a replacement from
the labor market. The FCA only estimates the actual
production that is lost during the time it takes to replace
the ill worker. Whereas the HCA reflects lost productive
potential, the FCA measures actual production losses.
Both methods have pros and cons, which has been
elaborately discussed elsewhere [15].Sensitivity analysis
Researchers perform sensitivity analysis for measuring
the degree of uncertainty. In sensitivity analysis, the key
variables (unit price, incidence or prevalence rate of
the diseases, discount rates, etc.) are changed to assess
the robustness of the result. Sensitivity analyses can beone-way, i.e., changing the parameter of one variable,
or multi-way, i.e., changing the parameter of two or more
variables. Probabilistic sensitivity analysis includes the
variables as a distribution and provides the probabilistic
behavior of a model [17].Literature search
We performed systematic literature searches in electronic
databases such as Medline (Pubmed), Embase, ECONbase,
EconLit, the Cumulative Index to Nursing and Allied
Health (CINAHL), The National Bureau of Economic
Research, the Latin American and Caribbean Literature
on Health Sciences Database (LILACS), and Popline. In
addition, we also searched the homepages of some major
international organizations such as the World Bank,
the WHO, Save the Children (UK & USA), the UK
Department for International Development (DFID), the
United Nations Children’s Fund (UNICEF), the United
Nations Population Fund (UNFPA), and Guttmacher
Institute. We also performed searches from the reference
lists of included studies and reviews. The search strategy
including keywords is presented in Annex 1 (Additional
file 1).
The article search was limited to the period January
1990 – April 2011. We selected studies in the English
language related to RMNCH and focusing economic
burden. Exclusion criteria were economic evaluation
studies related to RMNCH, such as cost minimization,
cost effectiveness, cost utility, and cost benefit analysis.
We also excluded notes, commentaries, and editorials
related to RMNCH and published in scientific journals.
The initial hits from the electronic databases were
exported to EndNote and checked for duplication. There-
after, we screened the articles by reading the abstracts.
We further searched for articles and reports on websites
of international organizations. We searched reference lists
of preliminarily selected articles and discussed disagreement
about any selection. Figure 1 provides a flow chart of the
article selection process.Results
The purpose of this review is not to discuss the strengths
and weaknesses of each individual article, but rather, to
give a general picture of the literature and discuss overall
methodological issues which might potentially influence
results, such as costing methods, cost items, discount
rate, etc.
The continuum of RMNCH covers a large portion of the
lifespan, from birth through reproductive age. We found
that all the studies addressed particular complications
or areas of RMNCH, e.g., non-exclusive breastfeeding,
preterm birth, tuberculosis, reproductive health, but not
RMNCH as an entire continuum. We have grouped the
Keywords search performed in Pubmed, Embase, Embosco (CNIHAL, EconLit), Popline, and 
The National Bureau of Economic Research
References exported to EndNote
n=17,783




Studies included for review
n=22
Included from reference list search, 
working papers, and international 
organizations
n=16
Excluded after discussion with authors, 
and thorough consideration 
n=86
Excluded after reading abstract
n=17,541
Figure 1 Flow chart depicting the process of the study selection for the systematic review.
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For better comparison, we have also converted costs to
international dollars (ID) based on purchasing power
parity (PPP) (2012).Breastfeeding
Two of the included studies estimate the cost for non-
optimal breastfeeding duration, one in the USA and the
other in the Netherlands. The US study [18] is an updated
version of a previous article [19], and considers diseases
which might be benefited by breastfeeding, such as lower
respiratory tract infection, atopic dermatitis, sudden infant
death syndrome, childhood leukemia, childhood asthma,
type 1 diabetes mellitus, and obesity. It reports that if 90%
of US families breastfed their child for 6 months (current
rate: 12.5%), this would save US$13 billion (2007 price
year) and prevent 911 deaths per year; if 80% did, this
would save US$10.5 billion and prevent 741 deaths per
year. Loss of earnings from premature death was a major
contributor to this loss, comprising US$9.5 billion (73%
of 13 billion), and may be overestimated because the
“revealed preference job risk” approach is not totallyunbiased [20]. However, the researchers considered the
benefits to the children only, while breastfeeding also
has potential health benefits for mothers. Consequently,
the calculated cost may not give a true picture.
By contrast, the Dutch study [21] considered benefits
of breastfeeding for both children and mothers. The
authors used the Netherlands Institute for Public Health
and the Environment (RIVM) chronic disease model [22]
to estimate national savings related to eight diseases/
disorders for children (otitis media, gastrointestinal
infection, asthma, respiratory infection, eczema, Crohn’s
disease, leukemia, and obesity) and three diseases for
mothers (rheumatic arthritis, premenopausal breast cancer,
and ovarian cancer). The total annual cost saving from
6 months’ exclusive breastfeeding was estimated to be
EUR50 million. The disease-specific costs were based
on data specific to the Netherlands.Preterm birth
Two studies [23,24] have estimated inpatient costs for
preterm births, one in Sweden and the other in the USA.
The costs were almost three times higher for preterm
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(<2,500 g) compared to normal weight, full term babies.
In the US study (24), costs are given as hospital-specific
cost-to-charge ratios, whereas in the Swedish study (23),
calculation of costs was based on Diagnostic Related
Group (DRG) criteria. The US study differentiates
between costs for infants and costs for mothers and
includes costs up to the baby’s discharge or death [24]. In
the USA, the median cost for very low birth weight
(VLBW), LBW, and normal weight babies is given as US
$93,481, US$7,141, and US$570, respectively (2003 prices).
By comparison, in Sweden, the cost for a preterm baby is
€20,263 (2000 prices). About 60% of mothers constituted
60% of the total maternal cost, whereas 5% of LBW and
VLBW children accounted for 75% of the child cost. The
time frame for these studies was 1 year. A UK-based study
estimating cost for the first 10 years of life [25] reports
that the long term inpatient care cost is 443% higher in
preterm compared to term babies. All three studies
conclude that cost decreases as the birth weight increases
and/or with term/near-term delivery [23-25].
One study investigated cost savings with delay of one
preterm delivery by ≥1 week [26]. The authors show that
with each week’s delay in delivery, the cost decreases.
Delaying deliveries at 29 weeks to 37 weeks would save
US$122,000 per case (2003 price year). The saving would
be even greater for deliveries at <26 weeks: US$206,000
per case. These estimations only consider inpatient costs.
However, LBW babies suffer from various comorbidities in
childhood and adulthood. Mangham et al. [27] calculated
the cost of preterm birth in England and Wales up to 18
years: to this purpose, they developed the Markov model
to analyze a hypothetical cohort of children to represent
the total number of live births in England and Wales.
These costs include hospital inpatient and outpatient
care, community health care, social care, and special
education cost. They considered only four types of dis-
ability with different levels of severity: motor (including
cerebral palsy), visual, and hearing impairment, and
development delay or cognitive disability. They gave
the total cost of preterm births in England and Wales
as US$4,567 billion (2006 price year) [27]. This may,
however, be an underestimation as only four types of
disability for children but no costs related to maternal
illness were considered.
One study [28] analyzed the lifelong cost of preterm
birth for mothers and children from a societal perspective.
Disabilities for preterm children considered were the same
as mentioned previously. Maternal care costs included the
costs of prenatal care, delivery services, costs associated
with pregnancy morbidity, and precautionary care.
Caregiver costs included travel costs and time costs
for caring for a preterm baby. However, the study did
not explicitly state whether the caregiver was formal orinformal. The total societal burden of preterm birth
was given as US$26.2 billion (2005 price year). The
indirect cost, US$5.7 billion, was for loss of household
and labor productivity [28]. The authors did not consider
productivity cost for premature death as they assumed
that all the infant deaths would be replaced and there
would be no productivity cost from premature death.
Although the collected cost data were for the whole
country, the data given represent only one state.
Tuberculosis
One study [29] estimating the global burden of tuberculosis
(TB) included only calculation of the productivity lost
due to TB-related morbidity and mortality. The morbidity-
related cost comprised a 30% reduction in average
productivity for 8.4 million sick people worldwide, i.e., US
$1 billion. Two million annual deaths cost an average loss
of income of US$11 billion, giving US$12 billion annually
for the TB burden. However, the study does not detail the
methodology of estimation.
John et al. [30] estimated the cost of tobacco consump-
tion in India, one of the complications being tuberculosis.
Using the prevalence-based attributable risk approach,
they estimated the relative risk (RR) of tobacco mortality
in a cohort of 99,570 people. Their data on inpatient
and outpatient cost of tobacco-related morbidity was
from a national sample survey. In 2004, TB accounted
for a cost of US$311 million in India. However, using
RR as attributable risk may be conservative although
the method is widely used in the literature. Moreover, the
cohort represents people aged ≥35 and may therefore
not capture the true effect of smoking. Furthermore,
the cost of premature death has not been included in
the analysis due to lack of data. The results may therefore
be an underestimation.
Reproductive health
Rein [31] measured the total economic burden of pelvic
inflammatory diseases (PIDs) in the USA from a health
care perspective. They analyzed 3 year PID claims data
to collect the unit cost, and used a probability model to
estimate the total disease burden and lifetime costs. The
lifetime cost was US$1,167/case at 1998 prices. Using a
Markov model, Yeh et al. [32] estimated the lifetime
costs for PID, from a societal perspective, in the USA.
Their cost calculation may be an overestimate as four
of the studies they collected data from were based on
some assumption which was not taken care of (e.g., not
nationally representative, dated inpatient cost). The
lifetime cost was US$1,060–3,180 per person at 2000
prices. Trent et al. [33] likewise calculated the direct
cost of PIDs, but for adolescents only. They collected
cost and claim rates from physicians and hospitals, a
total of US$3,025 per episode, for 1 year in 2009.
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infection in the USA for 2003–2007 from a third party
payer (employer and private insurance) perspective. They
collected disease rates in 7,301 males and 26,313 females
from insurance databases. The average cost was US$157
for males and US$141 for females. Considering the
total annual incidence of around 2.8 million, this cost is
enormous from an employer perspective. Blandford
and Gift [35] estimated the lifetime productivity cost
attributable to Chlamydia trachomatis using the Monte
Carlo model with the HCA. The study was limited to
women aged 15–44. The mean weighted productivity
loss was approximately US$130 dollar per untreated
chlamydia infection and US$649 per PID (2001 prices).
Pultorak et al. [36] calculated direct medical costs of
chlamydia, gonorrhea, and syphilis in the USA. They
concluded that the incidence is higher among 20–24-
year-olds and blacks. The cost burden was US$69.7 mil-
lion for 2 years at 2007 prices. However, they may have
underestimated costs because many STD cases are not
reported and remain undiagnosed.
Chesson et al. [37] estimated the costs of sexually
transmitted diseases (STDs) in 15–24-year-olds in the
USA. They considered direct costs for eight major diseases:
HIV/AIDS, human papillomavirus (HPV), genital herpes
simplex virus type 2, hepatitis 2, hepatitis B, chlamydia,
gonorrhea, trichomoniasis, and syphilis. The total burden
was estimated to be US$6.5 billion (2000 price year). In
an earlier report [38], the disease burden for the same
eight diseases in the USA was estimated at US$8.6 billion
(1997 prices).
Cost of illness studies on genital warts are mainly from
developed countries and give third party payer perspectives
[39-43]. In most cases, prevalence and incidence rates
are based on epidemiological studies and extrapolated
for the whole country. All the articles provide the age- and
gender-specific distribution of diseases. All show that the
peak occurrence of the disease happens later in life in men
than in women. The cost estimations are based on patient
registry databases throughout. None of the studies used
prospective cost analysis. Insanga et al. [41] included
inpatient care costs, whereas others did not. The duration
in all included studies on genital warts was 1 year except
for a study from Canada [43], which spanned 8 years.
Discussion
All the studies reviewed considered particular compli-
cations related to RMNCH, which all cost substantial
resources. For example, non-exclusive breastfeeding cost
ID14.39 billion in the USA compared to ID56 million
in the Netherlands. Preterm birth cost ID2.96 billion
and ID30.80 billion in the USA. Genital warts cost
ID186 million in the USA, ID23 million in Australia,
and ID1.35 million in Canada.Different approaches used for estimating direct and
indirect costs have, however, limited the comparability
of studies. Important methodological limitations are:
reliance on administrative datasets without checking data
quality; failure to clarify the perspective of analysis, and
omission of key cost items; small sample sizes and
selection bias; lack of sensitivity analysis; use of charges
or inadequately described costing methods; lack of
controls; inadequate follow-up; and failure to include
discounting in longer-term studies. Most studies do
not disaggregate costs into their components, making it
difficult to target the source and predictors of high costs.
All the cost estimations ignore at least some potentially
important components of costs and are therefore likely to
underestimate true resource use. These cost components
include professional fees, transportation costs, maternal
pregnancy complications, postpartum complications and
out of pocket costs for parents, and informal care costs.
There is almost no information on the lost earnings of
parents and other family members for infant care or on
productivity losses regarding the infants themselves.
One key issue is the inclusion of comorbidities for
particular health problems. Improved study designs and
long term cohorts are providing important epidemiological
findings, but agreement still needs to be reached in the
scientific community about the diseases benefited by
particular interventions. For example, the US study [18]
has included type 1 diabetes in its estimation, whereas the
Dutch study [21] does not include breastfeeding in its COI
calculations. Type 1 diabetes has significant cost burdens
throughout life [44]. The same issue has been examined in
preterm birth studies [25-28], where LBW was reported to
affect many diseases through infancy, childhood, and even
adulthood. The cost and benefits for both infant and
mother are interlinked and most of the studies have failed
to capture this. Regarding breastfeeding, the US study [18]
does not include any benefit to the mothers, whereas the
Dutch study [21] includes three diseases that may be
benefited by exclusive breastfeeding, with substantial cost
reduction. Maternal costs for delivery and hospitalization
and the costs of antenatal admission are excluded in most
studies. There also is a risk of double counting when
calculating both maternal and child cost together. The
analysis of cost for infants and mothers can be done
separately, with possible risk of underestimation of the
costs of prematurity and the possibility of missed shifting
of costs between the two groups. Regarding preterm
births, few studies have addressed educational costs, and
those that have, do not provide adequate information
across the spectrum of school age and disability.
Many of the studies are based on disease-specific costs
collected from the literature [18,21,26-28,37]. This is a
common practice in COI research; there needs to be some
adjustment in, as well as agreement on, the transferability
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stated whether they were the result of systematic reviews.
Also, the methodology for costing and cost adjustment is
not given, e.g., prevalence-based vs. incidence-based, or a
bottom-up vs. a top-down approach [16,45].
The HCA is the most popular method for estimating
loss of productivity cost in societal perspective studies.
Using an average wage rate for the total population
has the advantage of encouraging social equity in the
distribution of health services and other resources, because
lost productivity resulting from morbidity and mortality
is valued equally across persons. However, this method
produces biased estimation because for some diseases, the
incidence is not distributed uniformly across populations.
A better strategy may be to take account of the age
distribution specific to the disease and the corresponding
wage rates specific to the affected age. None of the studies
have tried to capture the intangible cost of STDs in terms
of human suffering, pain, grief, and social stigma. More-
over, the harmful impact of STDs on infants leads to long
term emotional suffering and stress for families, which is
almost impossible to capture in monetary terms. But this
cost may theoretically be included in the estimation.
We also found disagreement regarding the indirect cost
of infant death. For example, in one study [18], the cost of
premature death of infants for any type of disease was US
$10.5 million; in another study [28], this cost was not
considered. The author argued that premature infants’
death and the loss of their productivity could be replaced.
Most of the studies obtained data on a particular cohort
or region and extrapolated this to the entire country.
Extrapolation of health care utilization and costs across
geographical areas is potentially confounded by differences
in demographics, including the underlying health status of
the populations, as well as by differences in health care de-
livery conventions by provider. For this reason, adjustment
of charges to costs and adjustments of costs for differences
across geographic areas may not be sufficient in projecting
cost estimates from one region to the nation as a whole.
Risk adjustment based on differences in population
characteristics and further adjustment for organizational
differences in care delivery may be required.
Some studies use decision analytic models to estimate
cost, e.g., the Markov model [27,32] and Monte Carlo
simulation [35]. Inclusion of models requires a clear
description of the assumptions and proper sensitivity
analysis to verify the uncertainty.
Some researchers argue that COI estimates largely
quantify transfers paid from one entity to another and are
not indicative of actual costs [13]. Moreover, intangible
costs, such as pain, suffering, grief, and social stigma,
caused by illness are largely ignored in COI studies.
Consequently, COI estimates may either substantially
overestimate or underestimate the true financial burdenof diseases. Furthermore, even if COI estimates correctly
quantify all costs, critics still question the value of the
estimates [11]. By focusing on health sector spending
and lost labor productivity only, COI studies provide only
a partial picture of the true macroeconomic impact of
disease. They fail to consider ways in which depleted
capital accumulation, investment in human capital, and
demographic change contribute to diminished economic
growth.
One prominent function of COI calculations is setting
priorities in decision making. What is important is not
the size of burden of a disease per se, but rather, how it
can be reduced by preventive and/or therapeutic inter-
ventions [46]. The rational use of resources to ensure
maximum benefits can only be ensured by economic
evaluation studies that account for costs of prevention
and treatment, as well as outcomes of the interventions.
Yet, reviews of economic evaluation focusing preventive
and therapeutic interventions of RMNCH are limited.
Therefore, the next step would be to systematically
gather evidence concerning RMNCH interventions which
have proven to be the best value for money.
One limitation of this study is that we only examined
English language articles; also, there may be a lack of items
weighting (Table 2). However, this is a first attempt to
discuss the cost burden of interlinked RMNCH issues
under one umbrella.
Conclusion
This study could serve as the basis for projecting disease
expenses and help international organizations like the
Partnership for Maternal, Newborn, and Child Health
(PMNCH) to pursue authorities to prevent diseases of/
manage RMNCH and related complications and thus
save societal resources.
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